Back to News
Market Impact: 0.3
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst EstimatesCompany Fundamentals
Denali Therapeutics reported a quarterly loss of $0.64 per share, narrower than the Zacks consensus estimate of a $0.69 loss. The loss also narrowed from $0.74 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
DNLI0.35
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge